HUTCHMED gains wider China drug coverage on NRDL, insurance
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) announced that following NHSA contract renewal the updated National Reimbursement Drug List (NRDL) effective Jan 1, 2026 will continue to include ELUNATE, ORPATHYS and SULANDA. In addition, TAZVERIK is included in the first edition of China’s National Commercial Health Insurance Innovative Drug List. Indications listed:…